Lenalidomide and prednisone for myelofibrosis

Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903

Ruben A. Mesa, Xiaopan Yao, Larry D. Cripe, Chin Yang Li, Mark Litzow, Elisabeth M. Paietta, Jacob M. Rowe, Ayalew Tefferi, Martin S. Tallman

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF). Forty-eight subjects with anemia (42 evaluable) received lenalidomide, 10 mg/d, with a 3-month low-dose prednisone taper. Ten subjects received 3 months, and 25 received 6 months of therapy. Myelosuppression was the main toxicity with 88% with ≥ grade 3 hematologic toxicity and 45%≥ grade 3 nonhematologic toxicity. There were responses in 10 subjects (23%) using the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)-defined clinical improvement of anemia in 8 (19%) and/or decreased spleen size in 4 (10%). Serial bone marrow analysis showed no resolution of disease-related fibrosis or angiogenesis. With a median follow-up of 2.3 years, 23 subjects are alive. Lenalidomide and prednisone for myelofibrosis evaluated through a multicenteredcooperative group mechanism is only modestly active and myelosuppresive. This study was registered at http:// clinicaltrials.gov as NCT00227591.

Original languageEnglish (US)
Pages (from-to)4436-4438
Number of pages3
JournalBlood
Volume116
Issue number22
DOIs
StatePublished - Nov 25 2010

Fingerprint

Primary Myelofibrosis
Oncology
Prednisone
Toxicity
Anemia
Bone
Fibrosis
Spleen
Bone Marrow
Research
lenalidomide
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Lenalidomide and prednisone for myelofibrosis : Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. / Mesa, Ruben A.; Yao, Xiaopan; Cripe, Larry D.; Li, Chin Yang; Litzow, Mark; Paietta, Elisabeth M.; Rowe, Jacob M.; Tefferi, Ayalew; Tallman, Martin S.

In: Blood, Vol. 116, No. 22, 25.11.2010, p. 4436-4438.

Research output: Contribution to journalArticle

Mesa, RA, Yao, X, Cripe, LD, Li, CY, Litzow, M, Paietta, EM, Rowe, JM, Tefferi, A & Tallman, MS 2010, 'Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903', Blood, vol. 116, no. 22, pp. 4436-4438. https://doi.org/10.1182/blood-2010-05-287417
Mesa, Ruben A. ; Yao, Xiaopan ; Cripe, Larry D. ; Li, Chin Yang ; Litzow, Mark ; Paietta, Elisabeth M. ; Rowe, Jacob M. ; Tefferi, Ayalew ; Tallman, Martin S. / Lenalidomide and prednisone for myelofibrosis : Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. In: Blood. 2010 ; Vol. 116, No. 22. pp. 4436-4438.
@article{37fb2065ce214155aff5f7e3b41cc341,
title = "Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903",
abstract = "A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF). Forty-eight subjects with anemia (42 evaluable) received lenalidomide, 10 mg/d, with a 3-month low-dose prednisone taper. Ten subjects received 3 months, and 25 received 6 months of therapy. Myelosuppression was the main toxicity with 88{\%} with ≥ grade 3 hematologic toxicity and 45{\%}≥ grade 3 nonhematologic toxicity. There were responses in 10 subjects (23{\%}) using the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)-defined clinical improvement of anemia in 8 (19{\%}) and/or decreased spleen size in 4 (10{\%}). Serial bone marrow analysis showed no resolution of disease-related fibrosis or angiogenesis. With a median follow-up of 2.3 years, 23 subjects are alive. Lenalidomide and prednisone for myelofibrosis evaluated through a multicenteredcooperative group mechanism is only modestly active and myelosuppresive. This study was registered at http:// clinicaltrials.gov as NCT00227591.",
author = "Mesa, {Ruben A.} and Xiaopan Yao and Cripe, {Larry D.} and Li, {Chin Yang} and Mark Litzow and Paietta, {Elisabeth M.} and Rowe, {Jacob M.} and Ayalew Tefferi and Tallman, {Martin S.}",
year = "2010",
month = "11",
day = "25",
doi = "10.1182/blood-2010-05-287417",
language = "English (US)",
volume = "116",
pages = "4436--4438",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - Lenalidomide and prednisone for myelofibrosis

T2 - Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903

AU - Mesa, Ruben A.

AU - Yao, Xiaopan

AU - Cripe, Larry D.

AU - Li, Chin Yang

AU - Litzow, Mark

AU - Paietta, Elisabeth M.

AU - Rowe, Jacob M.

AU - Tefferi, Ayalew

AU - Tallman, Martin S.

PY - 2010/11/25

Y1 - 2010/11/25

N2 - A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF). Forty-eight subjects with anemia (42 evaluable) received lenalidomide, 10 mg/d, with a 3-month low-dose prednisone taper. Ten subjects received 3 months, and 25 received 6 months of therapy. Myelosuppression was the main toxicity with 88% with ≥ grade 3 hematologic toxicity and 45%≥ grade 3 nonhematologic toxicity. There were responses in 10 subjects (23%) using the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)-defined clinical improvement of anemia in 8 (19%) and/or decreased spleen size in 4 (10%). Serial bone marrow analysis showed no resolution of disease-related fibrosis or angiogenesis. With a median follow-up of 2.3 years, 23 subjects are alive. Lenalidomide and prednisone for myelofibrosis evaluated through a multicenteredcooperative group mechanism is only modestly active and myelosuppresive. This study was registered at http:// clinicaltrials.gov as NCT00227591.

AB - A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF). Forty-eight subjects with anemia (42 evaluable) received lenalidomide, 10 mg/d, with a 3-month low-dose prednisone taper. Ten subjects received 3 months, and 25 received 6 months of therapy. Myelosuppression was the main toxicity with 88% with ≥ grade 3 hematologic toxicity and 45%≥ grade 3 nonhematologic toxicity. There were responses in 10 subjects (23%) using the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)-defined clinical improvement of anemia in 8 (19%) and/or decreased spleen size in 4 (10%). Serial bone marrow analysis showed no resolution of disease-related fibrosis or angiogenesis. With a median follow-up of 2.3 years, 23 subjects are alive. Lenalidomide and prednisone for myelofibrosis evaluated through a multicenteredcooperative group mechanism is only modestly active and myelosuppresive. This study was registered at http:// clinicaltrials.gov as NCT00227591.

UR - http://www.scopus.com/inward/record.url?scp=78649475876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649475876&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-05-287417

DO - 10.1182/blood-2010-05-287417

M3 - Article

VL - 116

SP - 4436

EP - 4438

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -